NerBloc, a botulinum toxin type B neuromuscular-blocking agent has showed improvement in TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) total score from baseline to week four compared with placebo in a double-blind placebo-controlled trial (Study 131).
Eisai has acquired the exclusive rights to develop and market botulinum toxin type B in Japan through an agreement it concluded with US based Elan Pharmaceuticals and Ireland-based Elan Pharma International in September 2000.